| Assessment Status | Rapid Review Complete |
| HTA ID | - |
| Drug | Afatinib |
| Brand | Giotrif® |
| Indication | As monotherapy is indicated for the treatment of Epidermal Growth Factor Receptor (EGFR) TKI-naïve adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation(s). |
| Assessment Process | |
| Rapid review commissioned | 01/10/2013 |
| Rapid review completed | 13/10/2013 |
| Rapid review outcome | Full HTA not recommended |